Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics

Table 1 Clinical characteristics of patients with DIPG and mHGG

Patient	Age at Diagnosis (years)	Sex	Primary Tumor	Treatment at Diagnosis	OS (months)	Time to Autopsy (hours)
1	7.7	Male	DIPG	XRT + bevacizumab, irinotecan	24.4	19
2	2.9	Male	DIPG	XRT	32.2	17.5
3	4.3	Male	DIPG	XRT + HDAC inhibitor	11.2	15.5
4	4.4	Male	DIPG	XRT + HDAC inhibitor	11.5	4.8
5	3.5	Male	DIPG	XRT + EGFR inhibitor	16.8	5.5
6	23.3	Male	DIPG	XRT + HDAC inhibitor	13.4	8
7	12.3	Female	DIPG	XRT + PARP inhibitor, TMZ	11.8	20
8	15.1	Female	Bi-thalamic HGG	XRT + bevacizumab, TMZ, irinotecan	13.2	8

DIPG diffuse intrinsic pontine glioma, HGG high-grade glioma, TMZ temozolomide, HDAC histone deacetylase, PARP poly ADP ribose polymerase, EGFR epidermal growth factor receptor, OS overall survival, XRT radiotherapy

ISSN: 2051-5960